

57 The Japan Public Health Center (JPHC)–Based Prospective Study was started in 1990
58 for cohort I and in 1993 for cohort II. Subjects were all registered Japanese residents in 11
59 public health center areas who were aged 40–69 years at the beginning of the baseline survey.
60 Details of the study design have been described previously (6). The institutional review board
61 of the National Cancer Center, Tokyo, Japan, approved the study. The participants in the
62 present study were subjects in the JPHC study who responded to the 5-year follow-up
63 questionnaire covering lifestyle factors, including food intake, in 1995–1999 at ages 45–74
64 years. This follow-up survey was used as the starting point in the present study. We did not
65 include one PHC area in the analysis because it had no incidence data and, therefore, we
66 identified 133,323 subjects as the study population. After excluding subjects with
67 non-Japanese nationality ($n = 51$), a late report of emigration occurring before the starting
68 point ($n = 184$), ineligibility due to incorrect birth date ($n = 7$), or duplicate enrollment ($n = 4$),
69 we established a population-based cohort of 133,077 subjects. After exclusion of 12,056
70 subjects who had died, moved away from the study area, or been lost to follow-up before the
71 starting point, 121,021 subjects were left as eligible. Among them, 98,466 subjects responded
72 to the questionnaire, yielding a response rate of 81.4%.

73 **Questionnaire**

74 We asked subjects to reply to a lifestyle questionnaire that covered sociodemographic
75 characteristics, medical history, smoking and drinking habits, diet, and so on. We designed the

76 food frequency questionnaire (FFQ) to estimate dietary intake from 138 food items and
77 validated it for the estimation of various nutrients and food groups (7). The FFQ asked
78 subjects about their usual intake of 138 food items during the previous year in standard
79 portions/units and nine frequency categories (never, 1–3 times/mo, 1–2 times/wk, 3–4
80 times/wk, 5–6 times/wk, once/d, 2–3 times/d, 4–6 times/d, and ≥ 7 times/d). Nineteen items
81 regarded fish and shellfish, including salted fish, dried fish, canned tuna, salmon or trout,
82 bonito or tuna, cod or flat fish, seabream, horse mackerel or sardine, mackerel pike or
83 mackerel, dried small fish, salted roe, eel, squid, octopus, prawn, short-necked clam or crab
84 shell, vivipara, *chikuwa* (fish paste product), and *kamaboko* (fish paste product). Standard
85 portion sizes for each food item were small (50% smaller), medium (within 50% of the
86 standard), and large (50% larger). We calculated food intake in grams per day by multiplying
87 frequency by standard portion size for each food item. We calculated daily intake of n-3
88 PUFAs and the specific PUFA, that is, EPA, DHA, DPA, ALA, and n-6 PUFA, using a FA
89 composition table of Japanese foods (8). For some food that was not included in the table, the
90 study used a developed (substituted) FA composition table (9). EPA, DPA, and DHA were
91 summarized as marine n-3 PUFAs.

92 We assessed validity among subsamples using the 138-item FFQ with 14-day (for one
93 subtropical area) or 28-day (for other areas) weighted dietary records (10). Based on 102 men
94 and 113 women in cohort I, Spearman rank correlation coefficients between each marine n-3

95 PUFA intake estimated from the FFQ and intake estimated from dietary records were as
96 follows: EPA, 0.38 and 0.45; DPA, 0.32 and 0.39; DHA, 0.34 and 0.37, for energy-adjusted
97 value in men and women, respectively. For ALA, total n-3, and total n-6, the values were 0.27
98 and 0.25; 0.21 and 0.34; and 0.30 and 0.21, respectively. For the n-6/n-3 ratio, the value for
99 the crude estimate was 0.40 and 0.37 in men and women, respectively.

100 We excluded subjects who had been diagnosed or reported as having cancer before the
101 starting point ($n = 4097$), who had missing data regarding FA intake ($n = 1182$), or who
102 reported extreme total energy intake (upper 2.5% or lower 2.5%). The final analysis included
103 88,574 subjects (41,382 men and 47,192 women).

104 **Follow-up and identification of CRC cases**

105 We followed subjects from the 5-year follow-up survey (1995–1999) until December
106 31, 2006; the average follow-up period was 9.3 years. We identified changes in residence
107 status, including survival, annually through the residential registry in each area or, for those
108 who had moved from the area, through the municipal office of the area to which they had
109 moved. Mortality data for persons in the residential registry are forwarded to the Ministry of
110 Health, Labor, and Welfare and are coded for inclusion in the national Vital Statistics database.
111 Residency registration and death registration are required by the Basic Residential Register
112 Law and Family Registry Law, respectively, and the registries are thought to be complete.
113 During the follow-up period in the present study, 8040 (9.1%) subjects died, 4167 (4.7%)

114 moved away from the study area, and 264 (0.3%) were lost to follow-up.

115 We identified incident data for CRC by active patient notification from major local
116 hospitals in the study area and from data linkage with population-based cancer registries. We
117 coded CRC cases according to the *International Classification of Diseases for Oncology*, 3rd
118 edition (11) (C18–C20). We conducted analyses of site-specific cancers: C18 for colon cancer
119 (C18.0–C18.5 for proximal colon cancer and C18.6–C18.7 for distal colon cancer) and C19
120 and C20 for rectal cancer. According to the depth of tumor invasion, invasive cases were
121 defined by cancer over a mucosal layer. In our cancer registry system, the proportion of cases
122 for which information was available from death certificates only was 2.5% for CRC.

123 **Statistical analysis**

124 We calculated person-years of follow-up for each subject from the starting point to the
125 date of cancer diagnosis, date of emigration from the study area, date of death, or end of the
126 follow-up (December 31, 2006), whichever came first. We censored subjects lost to follow-up
127 at the last confirmed date of presence in the study area. The present analysis accrued a total of
128 380,682 and 447,151 person-years for men and women, respectively.

129 We calculated relative risks (RRs) and 95% confidence intervals (CIs) of developing
130 CRC for the categories of energy-adjusted FA consumption in quintiles for men and women
131 separately, with the lowest consumption category as the reference. A residual model was used
132 for energy adjustment (12). We used Cox proportional hazards models with adjustment for

133 potential confounding variables such as age in years (<49, 50–54, 55–59, 60–64, 65–69, and
134 >70); PHC area; body mass index (BMI; <24.9, 25–26.9, 27–29.9, and >30); smoking status
135 (never, past, and current); alcohol drinking in grams of ethanol per week (none, occasional,
136 1–149, 150–299, 300–449, and ≥ 450 g/wk); diabetes mellitus (DM; medication use or
137 history); physical activity in metabolic equivalent task (MET)-hours per day (quartile);
138 screening examinations (fecal occult blood test, barium enema, or colonoscopy) for CRC; and
139 quintiles of total calorie, energy-adjusted intake of calcium, vitamin D, fiber, and red meat.
140 The effects of the interaction of each FA and selected environmental factors such as calcium,
141 fiber, and vitamin D were also assessed by adding a multiplicative interaction term to the
142 model. We calculated trend P by assigning a median value in each category. All P values are
143 two-sided, and statistical significance was determined at the $P < 0.05$ level. We performed all
144 statistical analyses with SAS software, version 9.1 (SAS Institute Inc., Cary, NC).

145

146 Results

147 During 827,833 person-years of follow-up, we identified 1268 new CRC cases (521
148 colon and 253 rectal for men; 350 colon and 144 rectal for women). Proximal and distal colon
149 cancer developed in 213 and 281 men and 204 and 125 women, respectively.

150 Table 1 shows the baseline characteristics of the study subjects according to quintile of
151 marine n-3 PUFA, total n-3 PUFA, and total n-6 PUFA in men and women (only the first,

152 third, and fifth quintiles are listed). Men and women with a high intake of these PUFAs were
153 more likely to be old; to have a history of or current use of medications for DM; to have
154 undergone CRC screening; and to have a higher intake of vitamin D, fiber, fish, vegetables,
155 dressing, cooking oil, fats, and other oils. In general, the proportions of overweight subjects
156 and red meat intake were higher among those with high total n-3 PUFA or n-6 PUFA intake or
157 low marine n-3 PUFA intake. Current smoking was less frequent among those with a high
158 intake of these PUFAs, except marine PUFAs in men. Calcium intake was distributed
159 differently between men and women. A U-shaped distribution was seen for total energy intake
160 among those with marine n-3 PUFA and total n-3 PUFA intakes.

161 Associations of marine n-3 PUFAs, ALA, and total n-3 and n-6 PUFAs, and their
162 ratios and risk of colon and rectal cancer in men and women are shown separately (Tables 2
163 and 3). In men, no association was found between these PUFAs and colon cancer overall
164 (Table 2). When cancers were restricted to invasive tumors, similar results were found (data
165 not shown). However, when cases were subdivided by tumor location, we observed
166 statistically significant risk reduction for EPA, DPA, and marine PUFA and proximal colon
167 cancer; *P* values for trend were 0.008, 0.02, and 0.047, respectively. Although not statistically
168 significant, the RR tended to decrease with ALA intake, and finally, total n-3 PUFA was
169 statistically significantly associated with a reduced risk of proximal colon cancer. Compared
170 to the lowest quintile, the RRs (95% CIs) of the second, third, fourth, and fifth quintiles of

171 total n-3 PUFA intake were 0.75 (0.43-1.32), 0.56 (0.29-1.08), 0.46 (0.22-0.97), and 0.42
172 (0.18-0.98), respectively (P for trend = 0.0496). Also, we observed reduced risk for n-6 PUFA
173 intake (P for trend = 0.04). In contrast, no association was observed between these PUFAs and
174 distal colon cancer. For rectal cancer, we observed the lowest RR for the third quintile across
175 all n-3 PUFAs, which was statistically significant for EPA, 0.51 (0.28–0.92), and marine
176 PUFA, 0.51 (0.27–0.95), respectively. A higher level of intake of these PUFAs did not further
177 reduce the risk of rectal cancer. We observed no apparent association for total n-6 PUFA and
178 the n-3/n-6 ratio.

179 For women, we observed a statistically significant reduced risk among marine n-3
180 PUFAs and each specific marine n-3 PUFA and colon cancer (Table 3). Compared to the
181 lowest quintile, the RR was about half for EPA, DHA, and DPA. We obtained similar results
182 for invasive colon cancer. Similar to men, the inverse associations for marine n-3 PUFAs and
183 their specific PUFA were more prominent in proximal colon compared to distal colon,
184 whereas some of the trend failed to reach statistical significance; for proximal colon cancer, P
185 values for trend of EPA, DHA, DPA, and marine n-3 PUFA were 0.07, 0.13, 0.02, and 0.19,
186 respectively. These trends became statistically significant when all colon cancers were
187 combined. ALA showed no association with colon cancer, and finally, for total n-3 PUFAs,
188 although a reduced risk was suggested by increased intake, it failed to reach statistical
189 significance ($P = 0.15$). For rectal cancer, we observed the lowest RR for the second quintile

190 across all n-3 marine PUFAs, but this was not statistically significant. We observed neither
191 association for total n-3 PUFA and rectal cancer nor for total n-6 PUFA, the n-3/n-6 ratio, and
192 colon and rectal cancer.

193 Further analyses to check the effect of stratification by smoking status and interaction with
194 selected factors such as calcium, fiber, and vitamin D intakes were conducted. When subjects
195 were limited to those who had never smoked, the RR was generally attenuated; for example,
196 the RR and 95% CI of the highest quintile of marine n-3 PUFAs for developing rectal cancer
197 among men became 0.79 and 0.16–3.87. However, the results are based on a relatively small
198 sample size (61 rectal cancers), and these subjects were kept in the analysis, as shown in Table
199 2. Among potential factors, we selected *a priori* calcium and fiber as luminal modifiers, based
200 on findings from a recent large case-control study including more than 1000 CRC cases (13)
201 and vitamin D based on our previous report on the risk of CRC (14). For men, an interaction
202 was suggested between calcium and n-3 PUFAs, and vitamin D and some types of marine n-3
203 PUFAs (EPA and DPA) among rectal cancer cases. For women, an interaction was suggested
204 between calcium and ALA among rectal cancer cases and vitamin D and n-3 PUFAs among
205 colon cancer cases. However, adding interaction terms to the model essentially did not alter
206 the results.

207

208 **Discussion**

209 In this large, population-based prospective study, which is characterized by high fish
210 consumption and a wide range of n-3 PUFA intakes, marine n-3 PUFAs and specific PUFAs
211 were inversely related to the risk of colon cancer in the proximal site in men. A similar trend
212 was observed in women and it became statistically significant when total colon cancers were
213 combined.

214 Environmental factors that could favor the development of proximal or distal colon
215 tumors include diet, physical activity, smoking, cholecystectomy, and so on (15).

216 Fermentation reactions leading to short-chain FA production are up to 8-fold higher in the
217 proximal compared to the distal colon (16). On the other hand, levels of the promutagenic
218 lesion O⁶-methyldeoxyguanosine, a marker of exposure to N-nitroso compounds, are higher in
219 the normal distal compared to the proximal colonic DNA of patients with CRC (17).

220 Therefore, it is possible that the main effects of PUFAs are more strongly related to the
221 proximal than the distal parts of the large bowel, and a harmful effect, if any, is likely to
222 appear in the distal site. To date, six cohort studies have investigated the relationship between
223 marine n-3 PUFAs and CRC risk, and two studies showed a decreased risk by analyzing
224 marine n-3 PUFA intake (18) or serum levels of DPA and DHA (19), but not all (5, 20–22).
225 Among them, only two studies (5, 18) demonstrated the results separately for the colon and
226 rectum, which showed similar results by site. No study separated the colon by proximal or
227 distal regions. This is the first prospective study to show the different results by subsite.

228 In contrast with the linear trend shown in marine n-3 PUFAs and colon cancer, the
229 dose response was not clear; rather, we observed a U-shaped association for rectal cancer in
230 men and women. As mentioned earlier, some harmful effect, if any, may be apt to appear in
231 the distal part of the large intestine. Several causes of such effects include cigarette smoking,
232 chemical contaminants in fish, presence of DM, and heterocyclic aromatic amines. Recently,
233 CRC has been included among tobacco-related cancers by the International Agency for
234 Research on Cancer (23). Interestingly, the association is known to be more pronounced in
235 rectal cancer. As stated earlier, the results were generally attenuated when subjects were
236 limited to those who had never smoked, which suggest that smoking might explain, to some
237 extent, the present findings. Nevertheless, when we calculated the RR with adjustment for
238 cigarette smoking, the effect of residual confounding may still exist. However, considering the
239 number of cigarettes per day (<20 or ≥ 20) for current smokers and lifetime smoking
240 (pack-years) for ever smokers in the adjustment for smoking status did not alter the results
241 from the original ones. Furthermore, treating age, BMI, physical activity (METs-hour) as well
242 as nutrient data as continuous variables also did not alter the results. According to a recent
243 report based on both separate and combined analyses of three large cohort studies in the
244 United States, the Nurses' Health Study, the Nurses' Health Study 2, and the Health
245 Professionals Follow-Up Study, higher intake of long-chain n-3 PUFAs and fish increases the
246 risk of type 2 DM (24). Long-chain n-3 PUFAs can lower glucose utilization, and the authors

247 suggest that increased circulating concentrations of glucose or interruption of
248 insulin-signaling pathways by toxins, such as dioxins and methyl mercury, may contribute to
249 the association. DM is a known risk factor for CRC, and it is possible that some harmful
250 effects may exist through this mechanism. Furthermore, it is also possible that heterocyclic
251 amines, formed as a byproduct of reactions during the cooking of fish at high temperatures,
252 have posed a potential risk for development of CRC (25–27). A review based on a large body
253 of literature spanning numerous cohorts from many countries and with different demographic
254 characteristics did not provide evidence to suggest a significant association between n-3 FAs
255 and cancer incidence (28). Our significant findings among colon cancers may be largely due
256 to the wide range of fish intake in our population.

257 Regarding n-6 PUFAs, we generally observed no association but rather an inverse
258 association for the proximal colon in men. This is in line with previous studies (29), but not all.
259 In a meta-analysis of LA, main n-6 PUFAs, and CRC risk, based on 11 case-control studies,
260 the pooled odds ratio per 21.3 g LA intake was calculated as 0.92 (0.85–1.08) for all subjects,
261 1.05 (0.90–1.23) for men, and 0.80 (0.66–0.98) for women (29). Similarly, based on four
262 cohort studies, the combined RR with high compared to low intakes of LA was calculated as
263 0.92 (0.70–1.22). On the other hand, significant or non-significant increased risks posed by
264 n-6 PUFAs were observed in studies not only for CRC (20, 22) but also for breast cancer in
265 specific situations (30, 31). Several reasons are plausible to explain the discrepancies among

266 studies. Dietary sources of n-3 and n-6 PUFAs include several common foods and, therefore,
267 the effects of n-6 PUFAs may be masked by those of n-3 PUFAs. Actually, on the basis of our
268 previous investigation, the top food in cumulative percentage contribution for n-3 and n-6
269 PUFAs assessed by the dietary record was “vegetable oils/vegetable oil, mixed,” which
270 contributed 25.2% and 35.2% of n-3 and n-6 PUFAs, respectively (10). Therefore, when
271 further adjusted for ALA or n-3 PUFA intake, the association in the proximal colon among
272 men was attenuated, and the trend was no longer significant (data not shown). In addition to
273 cooking oil, n-6 PUFAs were contributed by many kinds of lean foods traditionally consumed
274 among Japanese such as rice, tofu (soybean curd), and miso. This is in contrast with the
275 contributors of n-6 PUFAs reported in the U.S. cohort: salad dressing, peanut butter, and
276 margarine (20). By means of observational study, it is actually difficult to completely
277 eliminate the effects of other nutrients included in these foods. Furthermore, because these
278 foods are consumed on a daily basis and might have small between-person variabilities, the
279 association, if any, might have been attenuated. Because of the marginally decreased risk of
280 CRC for n-3 PUFAs and no association for n-6 PUFAs, the ratio also did not indicate any
281 association.

282 This study has several possible limitations. First, we could not adjust for the effect of
283 use of nonsteroidal anti-inflammatory drugs, which may act as anti-inflammatory agents
284 through common pathways to n-3 PUFAs. However, considering the various mechanisms

285 involved in PUFA intake and CRC risk, the extent of this influence might not be so large.
286 Second, although the validity of PUFA intakes was reasonably high for each marine n-3 PUFA,
287 the validities of ALA, total n-3 PUFAs, and total n-6 PUFA intakes were relatively low. This
288 may be due to the difficulty of assessing “vegetable oils,” which are the main common source
289 of these PUFAs. Therefore, caution is needed in interpreting results for these PUFAs. Third,
290 because we conducted multiple comparisons in the analyses, including the differences
291 between colon and rectum and between proximal and distal colon, an interaction effect, some
292 results may be explained, in part, by chance. However, the observed associations were
293 generally consistent for both men and women and also could be reasonably explained by the
294 previously mentioned mechanisms.

295 The advantage of the study was its prospective design, which enabled us to avoid
296 exposure recall bias. We selected subjects from the general population, we kept the sample
297 size large, the response rate for the questionnaire was acceptable for studies of settings like
298 this, and the number of subjects lost to follow-up was negligible. In addition, the cancer
299 registry was of sufficient quality to reduce the misclassification of the outcome. Japanese
300 people consume much more fish than Western individuals and the Japanese diet has a greater
301 variation of n-3 marine PUFA intake. Based on data from 28 countries with diet recalls,
302 weighing records, or FFQ, in comparison with the United States and most of the European
303 countries, the mean daily intake of combined EPA and DHA among adults was about 5 times

304 and 2-3 times higher in Japan, respectively (32). Furthermore, using random sampling
305 methods in six regions in Japan, serum n-3 PUFA levels varied significantly by region, which
306 corresponded to the differences in fish consumption (33). In a previous report from our study
307 based on the baseline questionnaire, we observed no association for fish, EPA, DHA, and the
308 n-3/n-6 ratio (5). Owing to the greater detail of the FFQ used in the present analysis compared
309 to that used for the previous report, the variation of marine-based n-3 PUFAs became larger;
310 the median of EPA and DHA intake for the highest group in the present study almost doubled
311 that for the previous one, and the validity of n-6 PUFAs was improved enough to conduct the
312 analysis. The substantial growth in number of observed cases (705 to 1268) also allowed us to
313 conduct more informative analysis by subsite of colon (proximal and distal).

314 In conclusion, our results from a population with high fish consumption and a wide
315 range of n-3 PUFA intakes suggest that PUFAs of marine origin may be inversely related to
316 the risk of cancer in proximal sites of the large bowel.

317

318 **Appendix**

319 Members of the JPHC Study Group (principal investigator: S. Tsugane): S. Tsugane,
320 M. Inoue, T. Sobue, and T. Hanaoka, Research Center for Cancer Prevention and Screening,
321 National Cancer Center, Tokyo; J. Ogata, S. Baba, T. Mannami, A. Okayama, and Y. Kokubo,
322 National Cardiovascular Center, Suita; K. Miyakawa, F. Saito, A. Koizumi, Y. Sano, I.

- 323 Hashimoto, T. Ikuta, and Y. Tanaba, Iwate Prefectural Ninohe Public Health Center, Ninohe; Y.
- 324 Miyajima, N. Suzuki, S. Nagasawa, Y. Furusugi, and N. Nagai, Akita Prefectural Yokote
- 325 Public Health Center, Yokote; H. Sanada, Y. Hatayama, F. Kobayashi, H. Uchino, Y. Shirai, T.
- 326 Kondo, R. Sasaki, Y. Watanabe, Y. Miyagawa, Y. Kobayashi, and M. Machida, Nagano
- 327 Prefectural Saku Public Health Center, Saku; Y. Kishimoto, E. Takara, T. Fukuyama, M. Kinjo,
- 328 M. Irei, and H. Sakiyama, Okinawa Prefectural Chubu Public Health Center, Okinawa; K.
- 329 Imoto, H. Yazawa, T. Seo, A. Seiko, F. Ito, F. Shoji, and R. Saito, Katsushika Public Health
- 330 Center, Tokyo; A. Murata, K. Minato, K. Motegi, and T. Fujieda, Ibaraki Prefectural Mito
- 331 Public Health Center, Mito; T. Abe, M. Katagiri, M. Suzuki, and K. Matsui, Niigata
- 332 Prefectural Kashiwazaki and Nagaoka Public Health Center, Kashiwazaki and Nagaoka; M.
- 333 Doi, A. Terao, Y. Ishikawa, and T. Tagami, Kochi Prefectural Chuo-higashi Public Health
- 334 Center, Tosayamada; H. Doi, M. Urata, N. Okamoto, F. Ide, and H. Sueta, Nagasaki
- 335 Prefectural Kamigoto Public Health Center, Arikawa; H. Sakiyama, N. Onga, H. Takaesu, and
- 336 M. Uehara, Okinawa Prefectural Miyako Public Health Center, Hirara; F. Horii, I. Asano, H.
- 337 Yamaguchi, K. Aoki, S. Maruyama, M. Ichii, and M. Takano, Osaka Prefectural Suita Public
- 338 Health Center, Suita; S. Matsushima and S. Natsukawa, Saku General Hospital, Usuda; M.
- 339 Akabane, Tokyo University of Agriculture, Tokyo; M. Konishi, K. Okada, and I. Saito, Ehime
- 340 University, Toon; H. Iso, Osaka University, Suita; Y. Honda, K. Yamagishi, S. Sakurai, and N.
- 341 Tsuchiya, Tsukuba University, Tsukuba; H. Sugimura, Hamamatsu University, Hamamatsu; Y.

342 Tsubono, Tohoku University, Sendai; M. Kabuto, National Institute for Environmental Studies,
343 Tsukuba; S. Tominaga, Aichi Cancer Center Research Institute, Nagoya; M. Iida, W. Ajiki,
344 and A. Ioka, Osaka Medical Center for Cancer and Cardiovascular Disease, Osaka; S. Sato,
345 Osaka Medical Center for Health Science and Promotion, Osaka; N. Yasuda, Kochi University,
346 Nankoku; K. Nakamura, Niigata University, Niigata; S. Kono, Kyushu University, Fukuoka;
347 K. Suzuki, Research Institute for Brain and Blood Vessels Akita, Akita; Y. Takashima and M.
348 Yoshida, Kyorin University, Mitaka; E. Maruyama, Kobe University, Kobe; M. Yamaguchi, Y.
349 Matsumura, S. Sasaki, and S. Watanabe, National Institute of Health and Nutrition, Tokyo; T.
350 Kadowaki, Tokyo University, Tokyo; M. Noda and T. Mizoue, International Medical Center of
351 Japan, Tokyo; Y. Kawaguchi, Tokyo Medical and Dental University, Tokyo; and H. Shimizu,
352 Sakihae Institute, Gifu.

353

354 **Acknowledgments:** We thank all staff members in each study area for their painstaking
355 efforts to conduct the survey and follow-up. The authors' responsibilities were as follows: ST
356 was principal investigator; MI conducted the study, managed the data collection; SS helped to
357 conduct the study, analyzed and interpreted the data, and prepared the manuscript. MI, NS, TS,
358 TY, and RT helped to conduct the study. All authors provided critical suggestions for revision
359 of the manuscript. None of the authors had a conflict of interest.

360 **References**

- 361 1. Riediger ND, Othman RA, Suh M, Moghadasian MH. A systemic review of the roles of n-3
362 fatty acids in health and disease. *J Am Diet Assoc* 2009;**109**:668–79.
- 363 2. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids
364 for the prevention of cancer: a review of potential mechanisms. *Am J Clin Nutr*
365 2004;**79**:935–45.
- 366 3. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, Engler MM,
367 Engler MB, Sacks F. Omega-6 fatty acids and risk for cardiovascular disease: a science
368 advisory from the American Heart Association Nutrition Subcommittee of the Council on
369 Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and
370 Council on Epidemiology and Prevention. *Circulation* 2009;**119**:902–7.
- 371 4. World Cancer Research Fund/American Institute for Cancer Research. *Food, nutrition,*
372 *physical activity, and the prevention of cancer: a global perspective.* Washington, DC:
373 American Institute for Cancer Research, 2007. 517p.
- 374 5. Kobayashi M, Tsubono Y, Otani T, Hanaoka T, Sobue T, Tsugane S. Fish, long-chain n-3
375 polyunsaturated fatty acids, and risk of colorectal cancer in middle-aged Japanese: the JPHC
376 study. *Nutr Cancer* 2004;**49**:32–40.
- 377 6. Tsugane S, Sobue T. Baseline survey of JPHC study—design and participation rate. Japan
378 Public Health Center–Based Prospective Study on Cancer and Cardiovascular Diseases. *J*

- 379 *Epidemiol* 2001;**11**(6 Suppl):S24–9.
- 380 7. Tsubono Y, Takamori S, Kobayashi M, Takahashi T, Iwase Y, Itoi Y, Akabane M,
381 Yamaguchi M, Tsugane S. A data-based approach for designing a semiquantitative food
382 frequency questionnaire for a population-based prospective study in Japan. *J Epidemiol*
383 1996;**6**:45–53.
- 384 8. Science and Technology Agency, eds. *Fatty acids, cholesterol, vitamin E composition tables*
385 *of Japanese foods* (in Japanese). Tokyo: Ishiyaku Shuppan, 1990. 182p.
- 386 9. Sasaki S, Kobayashi M, Tsugane S. Development of substituted fatty acid food composition
387 table for the use in nutritional epidemiologic studies for Japanese populations: its
388 methodological backgrounds and the evaluation. *J Epidemiol* 1999;**9**:190–207.
- 389 10. Kobayashi M, Sasaki S, Kawabata T, Hasegawa K, Tsugane S. Validity of a
390 self-administered food frequency questionnaire used in the 5-year follow-up survey of the
391 JPHC Study Cohort I to assess fatty acid intake: comparison with dietary records and serum
392 phospholipid level. *J Epidemiol* 2003;**13**(1 Suppl):S64–81.
- 393 11. World Health Organization. *International classification of diseases for oncology*, 3rd ed.
394 Geneva, Switzerland: World Health Organization, 2000. 490p.
- 395 12. Willett WC. *Nutritional epidemiology*, 2nd ed. New York: Oxford University Press, 1998.
396 514p.
- 397 13. Kato I, Majumdar AP, Land SJ, Barnholtz-Sloan JS, Severson RK. Dietary fatty acids,

- 398 luminal modifiers, and risk of colorectal cancer. *Int J Cancer* 2010;**127**:942–51.
- 399 14. Ishihara J, Inoue M, Iwasaki M, Sasazuki S, Tsugane S. Dietary calcium, vitamin D, and
400 the risk of colorectal cancer. *Am J Clin Nutr* 2008;**88**:1576–83.
- 401 15. Iacopetta B. Are there two sides to colorectal cancer? *Int J Cancer* 2002;**101**:403–8.
- 402 16. Macfarlane GT, Gibson GR, Cummings JH. Comparison of fermentation reactions in
403 different regions of the human colon. *J Appl Bacteriol* 1992;**72**:57–64.
- 404 17. Povey AC, Hall CN, Badawi AF, Cooper DP, O'Connor PJ. Elevated levels of the
405 pro-carcinogenic adduct, O(6)-methylguanine, in normal DNA from the cancer prone regions
406 of the large bowel. *Gut* 2000;**47**:362–5.
- 407 18. Hall MN, Chavarro JE, Lee IM, Willett WC, Ma J. A 22-year prospective study of fish,
408 n-3 fatty acid intake, and colorectal cancer risk in men. *Cancer Epidemiol Biomarkers Prev*
409 2008;**17**:1136–43.
- 410 19. Kojima M, Wakai K, Tokudome S, Suzuki K, Tamakoshi K, Watanabe Y, Kawado M,
411 Hashimoto S, Hayakawa N, Ozasa K, Toyoshima H, Suzuki S, et al; JACC Study Group.
412 Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study.
413 *Am J Epidemiol* 2005;**161**:462–71.
- 414 20. Daniel CR, McCullough ML, Patel RC, Jacobs EJ, Flanders WD, Thun MJ, Calle EE.
415 Dietary intake of omega-6 and omega-3 fatty acids and risk of colorectal cancer in a
416 prospective cohort of U.S. men and women. *Cancer Epidemiol Biomarkers Prev*

- 417 2009;**18**:516–25.
- 418 21. Terry P, Bergkvist L, Holmberg L, Wolk A. No association between fat and fatty acids
419 intake and risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2001;**10**:913–4.
- 420 22. Pietinen P, Malila N, Virtanen M, Hartman TJ, Tangrea JA, Albanes D, Virtamo J. Diet
421 and risk of colorectal cancer in a cohort of Finnish men. *Cancer Causes Control*
422 1999;**10**:387–96.
- 423 23. Secretan B, Straif K, Baan R, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L,
424 Guha N, Freeman C, Galichet L, Cogliano V; WHO International Agency for Research on
425 Cancer Monograph Working Group. A review of human carcinogens—part E: tobacco, areca
426 nut, alcohol, coal smoke, and salted fish. *Lancet Oncol* 2009;**10**:1033–4.
- 427 24. Kaushik M, Mozaffarian D, Spiegelman D, Manson JE, Willett WC, Hu FB. Long-chain
428 omega-3 fatty acids, fish intake, and the risk of type 2 diabetes mellitus. *Am J Clin Nutr*
429 2009;**90**:613–20.
- 430 25. Cross AJ, Ferrucci LM, Risch A, Graubard BI, Ward MH, Park Y, Hollenbeck AR,
431 Schatzkin A, Sinha R. A large prospective study of meat consumption and colorectal cancer
432 risk: an investigation of potential mechanisms underlying this association. *Cancer Res*
433 2010;**70**:2406–14.
- 434 26. Rohrmann S, Hermann S, Linseisen J. Heterocyclic aromatic amine intake increases
435 colorectal adenoma risk: findings from a prospective European cohort study. *Am J Clin Nutr*